Literature DB >> 2335819

Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.

E Fenouillet1, J C Gluckman, E Bahraoui.   

Abstract

We have shown that enzymatic removal of N-linked glycans from human immunodeficiency virus type 1 (HIV-1) recombinant envelope glycoproteins gp160 and gp120 produced in BHK-21 cells did not significantly reduce their ability to bind to CD4, the cellular receptor for the virus. Because recombinant proteins may behave differently from proteins present on virions, we investigated whether such viral envelope glycoproteins either in a purified form or present on viral particles could be deglycosylated by treatment with an endoglycosidase F-N-glycanase mixture which cleaves all accessible glycan moieties. Endoglycosidase analysis of the carbohydrate composition of purified viral gp120 (vgp120) indicated a glycosylation pattern similar to that for recombinant gp120 (rgp120), and treatment with endoglycosidase F-N-glycanase resulted in comparable molecular weight (MW) reduction for both molecules. Similarly, after immunoblotting of the deglycosylated viral preparation, the characteristic 160- and 120-kilodalton (kDa) bands were replaced by 90- and 60-kDa bands, respectively. The apparent MW of gp41 shifted to 35 kDa. These results are consistent with complete deglycosylation. The immunoreactive conformation of envelope glycoproteins remained unaltered after deglycosylation: they were recognized to the same extent by specific human polyclonal or mouse monoclonal antibodies, and no proteolysis of viral proteins occurred during enzymatic treatment. Deglycosylation of vgp120 resulted in a less than 10-fold reduction of the ability to bind to CD4, presented either in a soluble form or at the cell membrane. In addition, deglycosylation significantly reduced, but did not abolish, HIV-1 binding to and infectivity of CD4+ cells as determined, respectively, by an indirect immunofluorescence assay and a quantitative dose-response infection assay. Taken together, these results indicate that removal of glycans present on mature envelope glycoproteins of HIV-1 diminishes but does not abolish either virus binding to CD4 or its capacity to infect CD4+ cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2335819      PMCID: PMC249466     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  HIV infection of monocytic cells: rôle of antibody-mediated virus binding to Fc-gamma receptors.

Authors:  T Jouault; F Chapuis; R Olivier; C Parravicini; E Bahraoui; J C Gluckman
Journal:  AIDS       Date:  1989-03       Impact factor: 4.177

2.  Operational and topological analyses of antigenic sites on influenza C virus glycoprotein and their dependence on glycosylation.

Authors:  K Sugawara; F Kitame; H Nishimura; K Nakamura
Journal:  J Gen Virol       Date:  1988-03       Impact factor: 3.891

3.  Predictions of linear T-cell and B-cell epitopes in proteins encoded by HIV-1, HIV-2 and SIVMAC and the conservation of these sites between strains.

Authors:  M J Zvelebil; M J Sternberg; J Cookson; A R Coates
Journal:  FEBS Lett       Date:  1988-12-19       Impact factor: 4.124

4.  Model for intracellular folding of the human immunodeficiency virus type 1 gp120.

Authors:  C Fennie; L A Lasky
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells.

Authors:  T Mizuochi; M W Spellman; M Larkin; J Solomon; L J Basa; T Feizi
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

6.  Aminosugar derivatives as potential anti-human immunodeficiency virus agents.

Authors:  A Karpas; G W Fleet; R A Dwek; S Petursson; S K Namgoong; N G Ramsden; G S Jacob; T W Rademacher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1.

Authors:  D C Montefiori; W E Robinson; W M Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Kozarsky; M Penman; L Basiripour; W Haseltine; J Sodroski; M Krieger
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

9.  Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis.

Authors:  E Fenouillet; B Clerget-Raslain; J C Gluckman; D Guétard; L Montagnier; E Bahraoui
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

10.  Effect of culture supernatant of MT-2 cells on human immunodeficiency virus-producing cells, MOLT-4/HIVHTLV-IIIB cells.

Authors:  T Matsuyama; Y Hamamoto; T Yoshida; Y Kido; S Kobayashi; N Kobayashi; N Yamamoto
Journal:  Jpn J Cancer Res       Date:  1988-02
View more
  33 in total

1.  Simple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4.

Authors:  V Chams; T Idziorek; P J Maddon; D Klatzmann
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Structural variability of env and gag gene products from a highly cytopathic strain of HIV-1.

Authors:  N Yahi; J Fantini; I Hirsch; J C Chermann
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Similar replication capacities of primary human immunodeficiency virus type 1 isolates derived from a wide range of clinical sources.

Authors:  W Lu; J M Andrieu
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Designed oligomers of cyanovirin-N show enhanced HIV neutralization.

Authors:  Jennifer R Keeffe; Priyanthi N P Gnanapragasam; Sarah K Gillespie; John Yong; Pamela J Bjorkman; Stephen L Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-28       Impact factor: 11.205

5.  The role of calcium and N-linked glycans in the oligomerization and carbohydrate binding properties of human immunodeficiency virus external envelope glycoprotein.

Authors:  M Haidar; N Seddiki; J C Gluckman; L Gattegno
Journal:  Glycoconj J       Date:  1994-04       Impact factor: 2.916

Review 6.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

7.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

8.  Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein.

Authors:  J N Reitter; R C Desrosiers
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques.

Authors:  J Overbaugh; L M Rudensey
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.